Literature DB >> 16768697

Making a virtue of necessity: managing the open abdomen.

Alan de Costa1.   

Abstract

BACKGROUND: The open abdomen, or laparostomy, is becoming increasingly used in the management of critically ill surgical patients.
METHODS: The published work on laparostomy is reviewed, in the light of personal experience, with particular attention to the history and pathophysiology associated with laparostomy. RESULTS AND
CONCLUSION: The combination of an inert plastic sheet in contact with the viscera, and the application of subatmospheric pressure on the wound, is an effective combination to maximize the prospects of delayed primary wound closure while minimizing the chance of fistula and ventral hernia.

Entities:  

Mesh:

Year:  2006        PMID: 16768697     DOI: 10.1111/j.1445-2197.2006.03638.x

Source DB:  PubMed          Journal:  ANZ J Surg        ISSN: 1445-1433            Impact factor:   1.872


  5 in total

1.  The open abdomen: temporary closure with a modified negative pressure therapy technique.

Authors:  Helene T Hougaard; Mark Ellebaek; Uffe T Holst; Niels Qvist
Journal:  Int Wound J       Date:  2014-06       Impact factor: 3.315

2.  Surgical classification of open abdomen: which clinical implications?

Authors:  Stefano Rausei; Gianlorenzo Dionigi; Francesca Rovera; Luigi Boni; Renzo Dionigi
Journal:  World J Surg       Date:  2010-03       Impact factor: 3.352

3.  Management of the open abdomen using combination therapy with ABRA and ABThera systems.

Authors:  Alfin N Mukhi; Samuel Minor
Journal:  Can J Surg       Date:  2014-10       Impact factor: 2.089

4.  Management of open abdomen with an absorbable mesh closure.

Authors:  Supparerk Prichayudh; Suvit Sriussadaporn; Pasurachate Samorn; Rattaplee Pak-Art; Sukanya Sriussadaporn; Kritaya Kritayakirana; Allan Capin
Journal:  Surg Today       Date:  2010-12-30       Impact factor: 2.549

Review 5.  Current status of the open abdomen treatment for intra-abdominal infection.

Authors:  Yujie Yuan; Jianan Ren; Yulong He
Journal:  Gastroenterol Res Pract       Date:  2013-10-02       Impact factor: 2.260

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.